Semaglutide vs. Tirzepatide: How the Two Leading GLP-1 Drugs Compare

Semaglutide and tirzepatide are the two most widely prescribed medications in the incretin class — the drugs behind brand names like Ozempic, Wegovy, Mounjaro, and Zepbound. They are related but not identical, and the differences matter when you and your clinician are deciding which one fits your situation. This is a plain-language comparison of how they line up.

The short version

Semaglutide is a GLP-1 receptor agonist: it mimics a single gut hormone, GLP-1, that helps regulate blood sugar and appetite. Tirzepatide is a dual GIP and GLP-1 receptor agonist: it acts on two hormone pathways at once. In head-to-head and trial data, tirzepatide has generally produced larger average weight loss and blood-sugar improvement — but both are effective, and "larger on average" is not the same as "better for you."

Weight loss

In its pivotal obesity trial, once-weekly semaglutide 2.4 mg (Wegovy) produced a mean weight loss of about 14.9% at 68 weeks, compared with 2.4% for placebo. Tirzepatide's pivotal obesity trial reported up to 20.9% at 72 weeks on the 15 mg dose. A direct diabetes comparison, SURPASS-2, found tirzepatide beat semaglutide 1 mg on both blood-sugar control and weight — though that study used a lower semaglutide dose than the one approved for weight management.

The practical takeaway: tirzepatide tends to produce more weight loss on average, but individual response varies widely, and the highest doses are not where everyone lands or needs to be.

Blood sugar

Both drugs are approved for type 2 diabetes and both lower A1c meaningfully. In SURPASS-2, tirzepatide produced larger A1c reductions than semaglutide across its dose range. For someone whose primary goal is glycemic control, either is a reasonable evidence-based option, and the choice often comes down to insurance, tolerability, and clinician judgment.

Side effects

The side-effect profiles are similar because both act on the GLP-1 pathway. The most common effects are gastrointestinal — nausea, diarrhea, constipation, and vomiting — and they tend to be worse when starting or increasing a dose, then ease over time. Slow dose escalation is the usual strategy for managing them. Both carry a boxed warning related to thyroid C-cell tumors seen in rodents and are not recommended for people with a personal or family history of medullary thyroid carcinoma or MEN 2.

Dosing and form

Both weight-management products are once-weekly self-injections. Semaglutide is also available as a daily oral tablet (Rybelsus) for type 2 diabetes, which tirzepatide is not. Both injectables are titrated upward over months to reach a maintenance dose, which is what keeps early nausea manageable.

How to choose

This is a decision for you and a prescriber who knows your history — not something to settle from a comparison table. Insurance coverage, out-of-pocket cost, supply, your other conditions, and how your body tolerates the first few doses often matter more than the average trial numbers. What the evidence supports is that both are effective; tirzepatide's averages are higher, and semaglutide has the longer track record and an oral option for diabetes.

This article is general information, not medical advice. Which medication — if any — is right for you depends on your health history and belongs in a conversation with your clinician.